174 related articles for article (PubMed ID: 20402712)
21. Pharmacological Treatment for Comorbid Bipolar Disorder and Obsessive-Compulsive Disorder in Adults.
Netto VM; Flores CA; Pallanti S
J Psychiatr Pract; 2020 Sep; 26(5):383-393. PubMed ID: 32936585
[TBL] [Abstract][Full Text] [Related]
22. Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania.
Berk M; Ng F; Wang WV; Tohen M; Lubman DI; Vieta E; Dodd S
J Affect Disord; 2008 Sep; 110(1-2):126-34. PubMed ID: 18280579
[TBL] [Abstract][Full Text] [Related]
23. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome in patients with bipolar I disorder, obsessive compulsive disorder or both.
Centorrino F; Hennen J; Mallya G; Egli S; Clark T; Baldessarini RJ
Hum Psychopharmacol; 2006 Apr; 21(3):189-93. PubMed ID: 16625524
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder.
Katagiri H; Takita Y; Tohen M; Higuchi T; Kanba S; Takahashi M
Curr Med Res Opin; 2012 May; 28(5):701-13. PubMed ID: 22356118
[TBL] [Abstract][Full Text] [Related]
26. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.
Husted DS; Shapira NA; Murphy TK; Mann GD; Ward HE; Goodman WK
J Psychiatr Res; 2007; 41(3-4):332-7. PubMed ID: 16860338
[TBL] [Abstract][Full Text] [Related]
27. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.
Lee JH; Dunner DL
Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265
[TBL] [Abstract][Full Text] [Related]
28. The antidepressant effects of risperidone and olanzapine in bipolar disorder.
McIntyre RS; Mancini DA; Srinivasan J; McCann S; Konarski JZ; Kennedy SH
Can J Clin Pharmacol; 2004; 11(2):e218-26. PubMed ID: 15520475
[TBL] [Abstract][Full Text] [Related]
29. Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.
Ohaeri JU
East Afr Med J; 2000 Feb; 77(2):86-92. PubMed ID: 10774081
[TBL] [Abstract][Full Text] [Related]
30. A NATURALISTIC EXPLORATORY STUDY OF OBSESSIVE-COMPULSIVE BIPOLAR COMORBIDITY IN YOUTH.
Masi G; Berloffa S; Mucci M; Pfanner C; D'Acunto G; Lenzi F; Liboni F; Manfredi A; Milone A
J Affect Disord; 2018 Apr; 231():21-26. PubMed ID: 29408159
[TBL] [Abstract][Full Text] [Related]
31. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression.
Brown E; Dunner DL; McElroy SL; Keck PE; Adams DH; Degenhardt E; Tohen M; Houston JP
Int J Neuropsychopharmacol; 2009 Jul; 12(6):773-82. PubMed ID: 19079815
[TBL] [Abstract][Full Text] [Related]
32. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF
J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630
[TBL] [Abstract][Full Text] [Related]
33. Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial.
Bobo WV; Epstein RA; Shelton RC
Hum Psychopharmacol; 2010 Jan; 25(1):30-6. PubMed ID: 20029794
[TBL] [Abstract][Full Text] [Related]
34. Clinical predictors of drug nonresponse in obsessive-compulsive disorder.
Shetti CN; Reddy YC; Kandavel T; Kashyap K; Singisetti S; Hiremath AS; Siddequehusen MU; Raghunandanan S
J Clin Psychiatry; 2005 Dec; 66(12):1517-23. PubMed ID: 16401151
[TBL] [Abstract][Full Text] [Related]
35. Phenomenological features and clinical impact of affective disorders in OCD: a focus on the bipolar disorder and OCD connection.
Timpano KR; Rubenstein LM; Murphy DL
Depress Anxiety; 2012 Mar; 29(3):226-33. PubMed ID: 22109969
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
Francobandiera G
Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793
[TBL] [Abstract][Full Text] [Related]
37. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
Bogan AM; Koran LM; Chuong HW; Vapnik T; Bystritsky A
J Clin Psychiatry; 2005 Jan; 66(1):73-9. PubMed ID: 15669891
[TBL] [Abstract][Full Text] [Related]
38. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.
Niufan G; Tohen M; Qiuqing A; Fude Y; Pope E; McElroy H; Ming L; Gaohua W; Xinbao Z; Huichun L; Liang S
J Affect Disord; 2008 Jan; 105(1-3):101-8. PubMed ID: 17531327
[TBL] [Abstract][Full Text] [Related]
39. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
40. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study.
Vieta E; Panicali F; Goetz I; Reed C; Comes M; Tohen M;
J Affect Disord; 2008 Feb; 106(1-2):63-72. PubMed ID: 17582508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
